Mankind Pharma, founded in 1995 by Ramesh and Rajeev Juneja, is India’s fourth-largest pharmaceutical company by domestic sales, headquartered in Delhi. It focuses on affordable, high-quality generics and consumer healthcare products, generating ₹10,335 crore in revenue in FY24 with a market capitalization of ₹121,193 crore. The company offers a diverse portfolio of over 500 products, including prescription drugs like antibiotics, cardiovascular, and gastrointestinal medicines, and over-the-counter brands such as Manforce, Prega News, and Gas-O-Fast, with the chronic segment contributing 36% of revenue, up from 18% in FY18. Mankind emphasizes accessibility through a strong supply chain and company-owned distribution network targeting rural markets to serve price-sensitive consumers. It operates six R&D centers, pioneering drugs like Dydrogesterone, and runs 25 manufacturing facilities adhering to international quality standards such as USFDA and WHO-GMP. Strategic acquisitions include Bharat Serums and Vaccines in 2024 for ₹13,630 crore to lead in women’s health and fertility, and Panacea Biotec’s formulations in 2022 for ₹1,872 crore. The OTC and consumer business, contributing 7% to revenue, was transferred to subsidiary Mankind Consumer Products to enhance focus, aiming for 15% contribution long-term. While operating in 34 countries, 97% of revenue comes from India, with plans to expand exports. Mankind’s growth strategy focuses on scaling chronic drugs, expanding into urban markets, and leveraging acquisitions, supported by a debt-free balance sheet and robust financials.